ERBB2 and breast cancer: Recently published TAILORx findings reported only on the RS < 11 patients (n = 1626), and demonstrated very low recurrence rates (rate of freedom from distant recurrence at 5 years: 99.3%; overall survival at 5 years, 98.0%).11 Prospective outcome data have also been presented from the WSG PlanB trial, where patients with HR + HER2-negative disease with node-positive or high risk node-negative early BC and RS ≤ 11 were recommended to omit adjuvant chemotherapy.